权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Study for relation between effect of anti-viral therapy and mutation of hepatitis B virus (HBV) in patients with chronic HBV infection.

慢性乙型肝炎病毒感染者抗病毒治疗效果与乙型肝炎病毒(HBV)突变关系的研究

基本信息

批准号：
14570491
负责人：
ORITO Etsuro
金额：
$ 2.18万
依托单位：
Nagoya City University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2002
资助国家：
日本
起止时间：
2002 至 2003
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14570491/
关键词：
HBV genotype lamivudine mutation chronic hepatitis B Genotype 慢性肝炎

项目摘要

In the patients with chronic hepatitis B virus (HBV) infection, we studied the relation between HBV mutations and clinical or virologic characteristics, including response to anti-viral therapy. First of all, we investigated the clinical differences among different HBV genotypes. In the patients with HBV/B, the frequency of HBeAg was low compared with those with HBV/C. Core promoter mutations in the patients with HBV/C were more frequently found than in those with HBV/B. Secondary, we found that the strains with HBV/B should be divided into two subtype, HBV/Ba, which is ubiquitous in Asia, and HBV/Bj, which is unique in Japan. Finally, we compared the response to anti-viral therapy (lamivudine) and HBV mutation in 31 patients with HBV genotype B (HBV/B) and 31 patients with HBV/C whose gender and age were matched. The effect for lamivudine therapy were same among both HBV/B and HBV/C groups. The mutations of HBV polymerase gene were developed during therapy however the frequency of resistant strain were same among both genotypes group. The effect and development of lamivudine resistant strain during therapy were also same between HBV/Ba and HBV/Bj groups. There was no relation between the mutations of the core promoter region and efficacy for lamivudine therapy. These data suggested that the mutations of the HBV polymerase gene, not the core promoter region, is linked to the effect of lamivudine therapy.

在慢性B型肝炎病毒（HBV）感染的患者中，我们研究了HBV变异与临床或病毒学特征，包括抗病毒治疗反应的关系。首先，我们调查了不同HBV基因型之间的临床差异。HBV/B型患者HBeAg阳性率较HBV/C型患者低。HBV/C组核心启动子突变频率高于HBV/B组。其次，我们发现HBV/B型毒株应分为两个亚型，亚洲普遍存在的HBV/Ba和日本特有的HBV/Bj。最后，我们比较了31名性别和年龄匹配的HBV基因型B（HBV/B）患者和31名HBV/C患者对抗病毒治疗（拉米夫定）和HBV突变的反应。拉米夫定治疗HBV/B组和HBV/C组的疗效相同。HBV聚合酶基因在治疗过程中发生突变，但耐药株的频率在两种基因型组中相同。HBV/Ba组和HBV/Bj组在治疗过程中拉米夫定耐药株的作用和发展也相同。核心启动子区的突变与拉米夫定治疗的疗效无关。这些数据表明，HBV聚合酶基因的突变，而不是核心启动子区，与拉米夫定治疗的效果。